Sugi Predict

Sugi Predict / Compounds / SCHEMBL1703575

SCHEMBL1703575

SCHEMBL1703575

O=C1c2ccccc2C(=O)N1CCCCCCCCO

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.70
▸ ALDH1A1 P00352 2/20 0.70
▸ MEN1 O00255 2/20 0.70
▸ KMT2A Q03164 2/20 0.70
▸ SMN1; SMN2 Q16637 2/20 0.70
▸ RGS12 O14924 1/20 0.70
▸ NPC1 O15118 1/20 0.70
▸ LMNA P02545 1/20 0.70
▸ PABPC1 P11940 1/20 0.70
▸ HTT P42858 1/20 0.70
▸ RECQL P46063 1/20 0.70
▸ RAB9A P51151 1/20 0.70
▸ TDP1 Q9NUW8 1/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ HDAC8 Q9BY41 3/20 0.61
▸ HDAC3 O15379 2/20 0.61
▸ HDAC4 P56524 2/20 0.61
▸ HDAC1 Q13547 2/20 0.61
▸ HDAC7 Q8WUI4 2/20 0.61
▸ HDAC2 Q92769 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3468337 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7544499 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7352888 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7285741 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7296911 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4179085 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17275126 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1448490 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1162502 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3468673 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108658792-A A kind of preparation method of 4- amino butanols 河南省化工研究所有限责任公司 2018-10-16 — — CN claimed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
CN-113045477-B Preparation method of fluorine-containing primary amine intermediate 中蓝晨光化工研究设计院有限公司 2022-11-01 — — CN disclosed
US-7138421-B2 Anti-androgenic pyrrolidines with tumor-inhibiting action SCHRING AKTIENGESELLSCHAFT (DE) 2006-11-21 — — US disclosed
US-20050159468-A1 Anti-androgenic pyrrolidines with tumor-inhibiting action BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-07-21 — — US disclosed
WO-2002016314-A1 SUBSTITUTED POLYAMINE COMPOUNDS H. LUNDBECK A/S (DK) 2002-02-28 — — WO disclosed
US-5652247-A VASOPRESSIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD (JP) 1997-07-29 — — US disclosed
US-5436254-A Vaopressin antagonists OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) 1995-07-25 — — US disclosed
EP-0602209-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-06-22 — — EP disclosed
EP-0382185-B1 Carbostyril derivatives OTSUKA PHARMA CO LTD (JP) 1994-06-15 — — EP disclosed
WO-1994001113-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1994-01-20 — — WO disclosed
US-5225402-A Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-07-06 — — US disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MEN1 4055/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MEN1 4055/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MEN1 4055/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MEN1 4055/4885
US-20050159468-A1 Anti-androgenic pyrrolidines with tumor-inhibiting action NR5A1, AR, CYP17A1 KDM4E 2146/4885ALDH1A1 531/4885MEN1 1271/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MEN1 4055/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885MEN1 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.